Neuralink’s 1st Human Trial Hits 100 Days, Raises Long-term Questions
After activation, the paralysed patient learned to control a cursor with neural signals, gaining thought-based control over a laptop as usability improved with training.
News
- OpenAI Flags Microsoft as a ‘Risk Factor’ Ahead of Potential IPO, Report Says
- Neuralink’s 1st Human Trial Hits 100 Days, Raises Long-term Questions
- Jensen Huang Says AGI is Here, and It Can Run Companies Too!
- Strikes Hit AWS Again as Tesla Moves to Cushion Gulf Disruption
- Starlink Lands in the UAE, But at a Premium
- AI Unreliability Top Concern Among Users, Reveals Anthropic Study
Noland Arbaugh, the first human recipient of Neuralink’s brain-computer interface, has completed 100 days with the implant, offering one of the most detailed accounts yet of how such systems perform outside controlled demonstrations. His experience provides an early, if still limited, window into the practical realities of consumer-facing neurotechnology.
Arbaugh, who has been paralysed from the shoulders down since a 2016 diving accident, described a relatively streamlined surgical and recovery process. The procedure involved implanting ultra-thin electrode threads into the motor cortex using a robotic system designed to minimize tissue damage.
According to his account, recovery was rapid, with visible healing within a week and no major complications reported.
The more consequential shift began after activation. Arbaugh learned to control a computer cursor using neural signals, initially through calibration exercises that mapped intent to movement. Over time, these interactions became more fluid, allowing him to perform tasks such as scrolling, clicking, and typing without physical input.
His account suggests that usability improves significantly with training. By connecting the interface to a MacBook, Arbaugh was able to navigate the operating system entirely through thought-based inputs.
Notably, Arbaugh’s use of the implant extended beyond basic accessibility functions. By approximately Day 80, he reported playing the online game World of Warcraft using only neural control. While gaming may appear incidental, it serves as a proxy for latency, precision, and sustained usability.
Still, the broader implications remain uncertain. Neuralink’s device is currently in clinical trials, and Arbaugh’s experience represents a single data point under closely monitored conditions. Questions around long-term reliability, signal stability, surgical scalability, and regulatory approval remain unresolved.
What his account does clarify is the trajectory of brain-computer interfaces as assistive technologies. Rather than fully restoring physical mobility, the current generation appears focused on enabling digital autonomy—allowing users to interact with software ecosystems independently.
Arbaugh’s reflection that the technology has already become integral to his daily life points to its immediate utility. But it also highlights a more measured reality: the path from experimental implant to widely accessible product will depend less on singular breakthroughs and more on sustained performance, safety, and integration into existing technological and regulatory frameworks.
